PEGylated biologics in haemophilia treatment: Current understanding of their long-term safety

Haemophilia. 2020 Jan;26(1):e11-e13. doi: 10.1111/hae.13875. Epub 2019 Nov 19.
No abstract available

Publication types

  • Letter

MeSH terms

  • Biological Products / adverse effects*
  • Biological Products / pharmacokinetics
  • Biological Products / therapeutic use*
  • Hemophilia A / blood
  • Hemophilia A / drug therapy*
  • Humans
  • Polyethylene Glycols / chemistry*
  • Risk Factors
  • Time Factors
  • Tissue Distribution / drug effects

Substances

  • Biological Products
  • Polyethylene Glycols

Grants and funding